Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Onychomycosis (Tinea Unguium) Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Onychomycosis (Tinea Unguium) Overview | 9 | 1 |
| Pipeline Products for Onychomycosis (Tinea Unguium) Comparative Analysis | 10 | 1 |
| Onychomycosis (Tinea Unguium) Therapeutics under Development by Companies | 11 | 1 |
| Onychomycosis (Tinea Unguium) Pipeline Products Glance | 12 | 4 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Unknown Stage Products | 15 | 1 |
| Onychomycosis (Tinea Unguium) Products under Development by Companies | 16 | 1 |
| Onychomycosis (Tinea Unguium) Companies Involved in Therapeutics Development | 17 | 15 |
| Almirall, S.A. | 17 | 1 |
| Anacor Pharmaceuticals, Inc. | 18 | 1 |
| Arno Therapeutics, Inc. | 19 | 1 |
| Blueberry Therapeutics Ltd | 20 | 1 |
| Crescita Therapeutics Inc. | 21 | 1 |
| Eisai Co., Ltd. | 22 | 1 |
| Helix BioMedix, Inc. | 23 | 1 |
| Hexima Limited | 24 | 1 |
| Meiji Seika Pharma Co., Ltd. | 25 | 1 |
| Moberg Pharma AB | 26 | 1 |
| NAL Pharmaceuticals Ltd. | 27 | 1 |
| Nihon Nohyaku Co., Ltd. | 28 | 1 |
| Novabiotics Limited | 29 | 1 |
| Novan, Inc. | 30 | 1 |
| Viamet Pharmaceuticals, Inc. | 31 | 1 |
| Onychomycosis (Tinea Unguium) Therapeutics Assessment | 32 | 9 |
| Assessment by Monotherapy Products | 32 | 1 |
| Assessment by Target | 33 | 2 |
| Assessment by Mechanism of Action | 35 | 2 |
| Assessment by Route of Administration | 37 | 2 |
| Assessment by Molecule Type | 39 | 2 |
| Drug Profiles | 41 | 27 |
| AN-2718 Drug Profile | 41 | 1 |
| AR-12 Drug Profile | 42 | 3 |
| BB-0305 Drug Profile | 45 | 1 |
| Drug for Onychomycosis Drug Profile | 46 | 1 |
| ELS-160 Drug Profile | 47 | 1 |
| fosravuconazole Drug Profile | 48 | 2 |
| HB-1275 Drug Profile | 50 | 1 |
| HXP-124 Drug Profile | 51 | 1 |
| luliconazole Drug Profile | 52 | 3 |
| ME-1111 Drug Profile | 55 | 1 |
| NAL-3216 Drug Profile | 56 | 1 |
| NP-213 Drug Profile | 57 | 1 |
| SB-208 Drug Profile | 58 | 1 |
| terbinafine Drug Profile | 59 | 3 |
| terbinafine Drug Profile | 62 | 1 |
| terbinafine Drug Profile | 63 | 1 |
| VT-1161 Drug Profile | 64 | 4 |
| Onychomycosis (Tinea Unguium) Dormant Projects | 68 | 3 |
| Onychomycosis (Tinea Unguium) Discontinued Products | 71 | 1 |
| Onychomycosis (Tinea Unguium) Product Development Milestones | 72 | 8 |
| Featured News &Press Releases | 72 | 1 |
| May 18, 2016: Moberg Pharma Announces Multiple Patent Approvals for MOB-015 | 72 | 1 |
| Mar 02, 2016: Viamet Reports Positive Results from Interim Analysis of RENOVATE Phase 2b Trial of VT-1161 in Onychomycosis | 72 | 1 |
| Jan 21, 2016: Moberg Pharma is contemplating a potential bond issue, updates financial targets and provides update on MOB-015 | 73 | 1 |
| Jan 07, 2016: Viamet to Present at the 3rd Annual Dermatology Summit | 74 | 1 |
| Aug 11, 2015: Nuvo Research Announces Grant of United States Patent for Topical Onychomycosis Formulation | 74 | 1 |
| Jul 15, 2015: Viamet to Present at American Podiatric Medical Association 2015 Annual Scientific Meeting | 75 | 1 |
| Mar 26, 2015: Moberg Pharma Announces Grant of EU Patent for MOB-015 Related to Topical Treatment of Onychomycosis (Nail Fungus) | 75 | 1 |
| Mar 13, 2015: MOB-015 Data To Be Presented At The 73rd Annual Meeting Of The American Academy Of Dermatology | 76 | 1 |
| Mar 10, 2015: Viamet Announces Initiation of RENOVATE Phase 2b Study of Oral VT-1161 in Onychomycosis | 76 | 1 |
| Feb 11, 2015: Moberg Pharma Announces Issue of U.S. Patent Related to MOB-015 for the Treatment of Onychomycosis | 77 | 1 |
| Sep 17, 2014: Moberg Pharma Announces Successful Results for MOB-015 in a Phase II Study for the Treatment of Onychomycosis | 77 | 1 |
| Sep 10, 2014: Data for Viamet s VT-1161 Presented at ICAAC 2014 | 78 | 1 |
| Dec 13, 2013: Moberg Pharma reports positive interim results in phase II clinical study of MOB-015 | 78 | 1 |
| May 27, 2013: Moberg Pharma Completes Enrollment In Phase II Clinical Trial Of MOB-015 | 79 | 1 |
| Nov 07, 2012: Moberg Derma Initiates Phase II Trial With MOB-015 For Treatment Of Onychomycosis | 79 | 1 |
| Appendix | 80 | 2 |
| Methodology | 80 | 1 |
| Coverage | 80 | 1 |
| Secondary Research | 80 | 1 |
| Primary Research | 80 | 1 |
| Expert Panel Validation | 80 | 1 |
| Contact Us | 80 | 1 |
| Disclaimer | 81 | 1 |